ArticleJournal of general internal medicine2025
Insulin Glargine Utilization and Spending Before and After the First Biosimilar Insulin Glargine: A Real-World Data Study.
Article in Journal of general internal medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsulin glargine Lantus® has been a top 10 Medicare Part D medication by spending for multiple years and was the only glargine until 2015. In 2016, Basaglar®, the first biosimilar referencing Lantus® was released. In 2020, the first biosimilar to achieve FDA-interchangeable designation, Semglee®, became available. This is the first large health-system study of utilization, costs, and savings attributable to alternative glargines.
objectiveUsing the University of California Health Data Warehouse, we assessed utilization, costs, and savings before and after alternative glargines introduction to inform access and policy considerations for patients with diabetes.
designRetrospective, observational, longitudinal study. PATIENTS: 110 659 glargine users with type I or II diabetes. MAIN MEASURES: Number and proportion of patients receiving Lantus®, Basaglar®, and Semglee® glargines daily, by age category with spending and savings estimates. KEY
resultsLantus® user proportion reduction after Basaglar® availability was associated with monthly spending reduction from $191 to $147 for patients under 65 and from $191 to $158 in those 65 and older from January 2015 to January 2022. Glargine users increased from 8 541 to 39 536 from 2012 to 2022. Basaglar® users increased from 6 on January 1st 2017 to 6 010 on January 1st 2022. Semglee® users increased from 29 on January 1st 2021 to 207 on January 1st 2022. Number treated for $100 000 increased after biosimilar availability, from 132 to 171 among patients under 65 and from 124 to 151 among patients 65 and older from 2015 to 2022. Annual savings attributable to biosimilars was $19.05 million in 2022 in the study population.
conclusionBasaglar® release was associated with spending reductions that accelerated after Semglee® availability. Biosimilar availability was associated with increases in glargine users and users per fixed-dollar amount. This study provides supportive evidence for biosimilar adoption policies. PRIMARY FUNDING SOURCE: None.
Identifiers
41188665What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.